Rakovina Therapeutics Statistics

Total Valuation

Rakovina Therapeutics has a market cap or net worth of CAD 17.61 million. The enterprise value is 18.75 million.

Market Cap	17.61M
Enterprise Value	18.75M

Important Dates

The next estimated earnings date is Friday, April 25, 2025.

Earnings Date	Apr 25, 2025
Ex-Dividend Date	n/a

Share Statistics

Rakovina Therapeutics has 90.29 million shares outstanding. The number of shares has increased by 7.36% in one year.

Current Share Class	n/a
Shares Outstanding	90.29M
Shares Change (YoY)	+7.36%
Shares Change (QoQ)	+26.81%
Owned by Insiders (%)	9.23%
Owned by Institutions (%)	n/a
Float	57.69M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	5.73
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-5.66
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.43, with a Debt / Equity ratio of 0.45.

Current Ratio	1.43
Quick Ratio	0.47
Debt / Equity	0.45
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-11.55

Financial Efficiency

Return on equity (ROE) is -89.48% and return on invested capital (ROIC) is -37.76%.

Return on Equity (ROE)	-89.48%
Return on Assets (ROA)	-34.30%
Return on Capital (ROIC)	-37.76%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +100.00% in the last 52 weeks. The beta is -0.62, so Rakovina Therapeutics's price volatility has been lower than the market average.

Beta (5Y)	-0.62
52-Week Price Change	+100.00%
50-Day Moving Average	0.13
200-Day Moving Average	0.10
Relative Strength Index (RSI)	61.10
Average Volume (20 Days)	257,258

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-3.05M
Pretax Income	-3.31M
Net Income	-3.31M
EBITDA	-2.52M
EBIT	-3.05M
Earnings Per Share (EPS)	-0.04

Full Income Statement

Balance Sheet

The company has 255,049 in cash and 1.40 million in debt, giving a net cash position of -1.14 million or -0.01 per share.

Cash & Cash Equivalents	255,049
Total Debt	1.40M
Net Cash	-1.14M
Net Cash Per Share	-0.01
Equity (Book Value)	3.07M
Book Value Per Share	0.03
Working Capital	358,060

Full Balance Sheet

Cash Flow

Operating Cash Flow	-2.47M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Rakovina Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.36%
Shareholder Yield	-7.36%
Earnings Yield	-22.65%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a